Genomic Enterprise

Costa FF (December, 2011) Basic research, applied medicine and EHRs - are  we on  the  right  track? Journal of Cancer Science and Therapy. In press.

Ramos EAS, Grochoski M,  Braun-Prado K, Seniski G, Cavalli I, Ribeiro EMSF, Camargo AA, Costa FF, Klassen G (November, 2011). Epigenetic changes of CXCR4 and its ligand CXCL12 as prognostic factors for sporadic breast cancer. PLoS ONE. In press.

Interviewed for a Feature article about Brazilian scientific rise and the economic crisis in the USA. Petherick A (October, 2011). Brazilians lured back home with research funding and stability. Nature Medicine (17) : 1173.

Costa FF, Bischof JM, Vanin EF, Lulla RR, Wang M, Sredni ST, Rajaram V, Bonaldo MF, Wang D, Goldman S, Tomita T, Soares MB. (July, 2011). Identification of microRNAs as potential prognostic markers in ependymoma. PLoS ONE. 6(10): e25114.

Coutinho MP & Costa FF (June, 2011). Social Media in Science and Medicine. G.I.T. Laboratory Journal. In press.

Lulla RR, Costa FF, Bischof JM, Chou PM, Bonaldo MF, Vanin EF, Soares MB (May, 2011). Identification of differentially expressed microRNAs in osteosarcoma. Sarcoma. In press.

Hamm C & Costa FF (May, 2011). The impact of epigenomics on future drug design and new therapies. Drug Discovery Today. In press.

Costa FF (April, 2011). Non-coding RNAs, epigenetics and complexity in human cells. Chapter for the Book Long Non-coding RNAs: Regulation of Gene expression and Drivers of Natural Selection - Horizon Scientific Press. In press.

Costa FF, Foly LS, Coutinho MP (March, 2011). DataGenno: building a new tool to bridge molecular and clinical genetics. The Application of Clinical Genetics. Vol 4: 45-54.

Dr Costa was appointed as a member of the Editorial Board for the Journal of Cancer Science and Therapy

Molognoni F, Cruz AT, Meliso FM, Morais AS, Souza CF, Xander P, Bischof JM, Costa FF, Soares MB, Liang G, Jones PA, Jasiulionis MG (February, 2011).Epigenetic reprogramming as a key contributor to melanocyte malignant transformation. Epigenetics. (4):450-464.

Costa FF (October, 2010).Non-coding RNAs: could they be the answer? Briefings in Functional Genomics. In press.

Costa FF (October, 2010). Epigenomics in cancer management. Cancer Management and Research. Vol 2: 255 - 265.

Ichi S, Costa FF, Bischof JM, Nakazakia H, Shena YW, Boshnjakua V, Mania-Farnellc B, McLonea DG, Tomita T, Soares MB, Mayanil CSK (September, 2010). Folic acid remodels chromatin on Hes1 and Neurog2 promoters during caudal neural tube development. Journal of Biological Chemistry. 285: 36922-36932.

Berkofsky-Fessler W, Buzzai M, Kim MK, Fruchtman S,
Najfeld V, Min DJ, Costa FF, Bischof JM, Soares MB, McConnell MJ, Zhang W, Levine R, Gilliland DG, Calogero R, Licht JD (July, 2010). Transcriptional profiling of Polycythemia Vera identifies gene expression patterns both dependent and independent from the action of JAK2V617F. Clinical Cancer Research. 6: 4339-4352.

Malchenko S,Galat V, Seftor E, Vanin EF, Costa FF, Seftor REB, Soares MB, Hendrix MJ (July, 2010).Cancer hallmarks in Induced Pluripotent Cells: new insights.Journal of Cellular Physiology. (Cover of the issue). 225: 390-393.

Our article in the NEWS: Science Daily and Lurie Cancer Center

Costa FF (July, 2010). Non-coding RNAs: Meet thy masters. Bioessays. 32 (7): 599-608 (Cover of the issue - Abstract Text and Photograph).

Mack GS & Marshall A (March, 2010). Interviewed and cited in a Feature article about cancer metastasis and drug development in the journal Nature Biotechnology entitled: "Lost in migration." Nat. Biotechnology. 28 (3): 214-229.

Costa FF (February, 2010). Non-coding RNAs: Old Molecules, new functions - Shifting paradigms in genomics? G.I.T. Laboratory Journal. Vol 8/9, 2010.

Sredni ST, Bonaldo MF, Costa FF, Chiang-Ching H, Hamm C, Rajaram V, Tomita T, Goldman S, Bischof JM, Soares MB (December, 2009). Upregulation of mir-221 and mir-222 in atypical teratoid/rhabdoid tumors: potential therapeutic targets. Childs Nervous System. 26, 279-283.

Costa FF (November, 2009). Genomics, epigenomics and personalized medicine - a bright future for drug development?
BioForum Europe. Vol. 13, 29-31.

Hamm CA, Xie H, Costa FF, Vanin EF, Seftor EA, Sredni ST, Bischof JM, Bonaldo MF, Hendrix MJC, Soares MB. (December, 2009). Global demethylation of rat chondrosarcoma cells after treatment with 5-Aza-2-deoxycytidine results in increased tumorigenicity. PLoS ONE. 4 (12): e8340.

Ramos EAS, Camargo AA, Prado KB, Slowik R, Cavalli IJ, Ribeiro ESF, Pedrosa FO, Souza EM, Costa FF and Klassen G (October, 2009). Simultaneous CXCL12 and ESR1 CpG island hypermethylation correlates with poor prognosis in sporadic breast cancer. BMC Cancer. 10: 23.

Lewandowska MA, Costa FF, Bischof JM, Williams SH, Soares MB, Harris A (September, 2009). Multiple mechanisms influence regulation of the CFTR gene promoter. American Journal of Cell and Respiratory Biology.43 (3): 334-341.

Costa FF, Seftor EA, Bischof JM, Kirschmann DA, Strizzi L, Arndt K, Bonaldo MF, Soares MB, Hendrix MJ (December, 2009). Epigenetically Reprogramming Metastatic Tumor Cells with an Embryonic Microenvironment. Epigenomics. Vol. 1, 2: 387-398.

Strizzi L, Hardy KM, Seftor EA, Costa FF, Kirschman D, Seftor RE, Postovit LM, Hendrix MJ. (September, 2009). Development and cancer: at the crossroads of Nodal and Notch signaling. Cancer Research. 69: 7131-7134.

Verbisck NV, Costa ET, Costa FF, Cavalher FP, Costa MDM, Muras A, Paixo VA, Moura RP, Granato MF, Ierardi DF, Machado T, Melo F, Ribeiro KB, Cunha IW, Lima VCC, Maciel MS, Carvalho AL, Soares F, Zanata SM, Sogayar MC,Chammas R, Camargo AA (June, 2009). ADAM23 negatively modulates v3 integrin activation during metastasis. Cancer Research. 69: 5546-5552.

Costa FF (April, 2009). Non-coding RNAs and new opportunities for the private sector. Drug Discovery Today. 14 (9-10): 446 - 452.

Among the most downloaded from Drug Discovery Today!

Costa FF, Klassen G (March, 2009). ADAM33 gene silencing by promoter hypermethylation as a molecular marker in breast invasive lobular carcinoma. BMC Cancer. 9 (1): 80.

Passetti F, Ferreira CG, Costa FF (February, 2009). The impact of microRNAs and alternative splicing in pharmacogenomics. Pharmacogenomics J. 9 (1): 1-13.

Maguire CA, Meijer DH, Leroy SG, Tierney LA, Broekman MLD, Costa FF, Breakefield XO, Stemmer-Rachamimov A, Sena-Esteves M (August, 2008) . Preventing growth of brain tumors by creating a zone of resistance. Molecular Therapy.16(10):1695-1702.
See the Press Release about our article here!

Costa FF (February, 2008).Non-coding RNAs, epigenetics and complexity. Gene:410 (1): 9-17.

Most downloaded article in Genetics from 2008 - 2009!

Wurdinger T, Costa FF (November, 2007). An expert commentary entitled The potential of miRNA modulators as targeted oncology therapies - an update. Spectrum Newspaper for Pharmaceutical Industry Dynamics - Dealmaking and Financing: 15-26, 15-27.

Wurdinger T, Costa FF (October, 2007). Molecular therapy in the microRNA era. Pharmacogenomics J: 7(5):297-304.

Postovit LM, Costa FF, Bischof JM, Seftor EA, Wen B, Seftor RE, Feinberg AP, Soares MB, Hendrix MJ (July, 2007).The commonality of plasticity underlying multipotent tumor cells and embryonic stem cells.J Cell Biochem: 101(4):908-17.

Mack GS (June, 2007). Interviewed and cited in a feature article in the Nature Biotechnology Journal entitled MicroRNA gets down to business. Nat. Biotechnology: 25 (6):.631-638.

Wurdinger T, Costa FF (May, 2007). A spectrum expert commentary entitled The potential of miRNA modulators as targeted oncology therapies. Spectrum Newspaper for Pharmaceutical Industry Dynamics: 5-25.

Costa FF, Le Blanc K, Brodin B (March, 2007). Concise review: cancer/testis antigens, stem cells and cancer. Stem Cells: 25 (3):707-11.

Selected article for the cover of the issue!

Costa FF (January, 2007). Non-coding RNAs: lost in translation? Gene: 386 (1-2):1-10.

Costa FF, Paixo VA, Cavalher FP, Ribeiro KB, Cunha IW, Rinck JA, O'Hare M, Mackay A, Soares FA, Brentani RR, Camargo AA (March, 2006). SATR-1 hypomethylation is a common and early event in breast cancer. Cancer Genetics and Cytogenetics: 165 (2):135-143.

Costa FF (September, 2005). Non-coding RNAs: new players in eukaryotic biology.Gene: 357(2):83-94.

Costa FF (August, 2005). Non-coding RNAs: functional molecules or a quality control error? A comment on: BabaK T, Blencowe BJ and Hughes TR. A systematic search for new mammalian noncoding RNAs indicates little conserved intergenic transcription. BMC Genomics: 6: 104.

Costa FF, Colin C, Shinjo SM, Zanata SM, Marie SK, Sogayar MC, Camargo AA (June, 2005). ADAM23 methylation and expression analysis in brain tumors. Neuroscience Letters: 380 (3): 260-4.

Costa FF, Verbisck NV, Salim AC, Ierardi DF, Pires LC, Sasahara RM, Sogayar MC, Zanata SM, Mackay A, O'Hare M, Soares F, Simpson AJ, Camargo AA (February, 2004). Epigenetic silencing of the adhesion molecule ADAM23 is highly frequent in breast tumors. Oncogene: 23 (7):1481-1488.

Pres Release of an article in the News Magazine ISTOE from South America entitled "Hope Lives Here" about cancer research and its impact in Brazil (Published in 2003).

See the article online and the PDF file

Abrantes EF, Pires EG, Carvalho AF, Costa FF, Savino W, Reis LF (June, 2003). Identification, structural characterization and tissue distribution of Tsg-5: a new TNF-stimulated gene. Genes and Immunity: 4 (4):298-311.

Fabricio F. Costa and Anamaria A. Camargo (2003). Bases da Oncologia 2nd edition - Chapter 5: Oncogenes and Tumor Supressor Genes(Book Chapter).

Almeida-Silva S, Costa FF, Mares-Guia ML, Williams P, Melo MN (November, 1998). Lutzomyia longipalpis: pH in the gut, digestive glycosidases, and some speculations upon Leishmania development. Experimental Parasitology. 90 (3): 212-219.